Overview

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double blind trial of combination therapy (Cimzia plus Azathioprine) versus mono therapy (Cimzia alone) and the improvement in mean SES-CD (Simple Endoscopic Scoring in Crohn's Disease) score. It is a trial where the investigators are administering biological therapy by itself and biological therapy plus an immunosuppressive medicine in combination to see which form of therapy has a better effect on healing ulcerations in the small intestine and colon that are due to a flare up of Crohn's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Gastroenterology Research of America
Collaborator:
UCB Pharma
Treatments:
Azathioprine
Certolizumab Pegol